INTEGRATE IIb: A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) »